Cellular senescence is a type of sustained cell-cycle arrest characterised by secretory characteristics in reaction to cellular stress. Historically, it was thought to be an endogenous evolutionary homeostatic system that eliminates damaged cells, especially those in danger of malignant transformation, and hence protects from tumours. However, the increase of senescent cells might have negative consequences, primarily because of the senescence-associated secretory phenotype, which has the ability to contribute to age-related illnesses such as carcinoma. In addition to acting as a tumour suppressor, cellular senescence is rapidly becoming recognised as a response generated in vivo in individuals with carcinoma to various anti-tumour medications. Its significance in tumours is uncertain and contentious, and senescence is currently being touted as a developing hallmark of cancer due to its signature-promoting qualities. Furthermore, the prognostic consequences of cellular senescence remain unappreciated because of the difficulty of identification and the scarcity of ex vivo and in vivo proof of cellular senescence in individuals with cancer, which has recently become available. This comprehensive study focuses on drug targets and signalling mechanisms involved in tumour cell senescence. The crucial functions of senolytics, anti-tumor drug-induced senescence, and other combined administrations in attenuating pathways of cellular senescence are investigated in order to prevent cancer as well as effective treatment. Current challenges, constraints, and potential developments are also addressed.